nach oben

Erschienen in:

23.03.2022 | Review Article

Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis

verfasst von: Jie Ning Yong, Cheng Han Ng, Chloe Wen-Min Lee, Yu Yi Chan, Ansel Shao Pin Tang, Margaret Teng, Darren Jun Hao Tan, Wen Hui Lim, Jingxuan Quek, Jieling Xiao, Yip Han Chin, Roger Foo, Mark Chan, Weiqin Lin, Mazen Noureddin, Mohammad Shadab Siddiqui, Mark D. Muthiah, Arun Sanyal, Nicholas W. S. Chew

Erschienen in: Hepatology International | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

Several studies have documented a relationship between non-alcoholic fatty liver disease (NAFLD) and structural heart disease, particularly diastolic function. This meta-analysis will be the first to examine the echocardiographic-derived cardiac function and structural characteristics in NAFLD patients, and its association with liver disease severity and metabolic profile.

Methods

Medline and Embase were searched and pairwise meta-analysis was conducted in DerSimonian and Laird to obtain the odds ratio (OR) and mean difference (MD) for dichotomous and continuous variables, respectively, to compare the effects of NAFLD on the echocardiography parameters.

Results

Forty-one articles involving 33,891 patients underwent echocardiography. NAFLD patients had worse systolic indices with lower ejection fraction (EF, MD: − 0.693; 95% CI: − 1.112 to − 0.274; p = 0.001), and worse diastolic indices with higher E/e’ (MD: 1.575; 95% CI: 0.924 to 2.227; p < 0.001) compared to non-NAFLD patients. NAFLD patients displayed increased left ventricular mass (LVM, MD: 34.484; 95% CI: 26.236 to 42.732; p < 0.001) and epicardial adipose thickness (EAT, MD: 0.1343; 95% CI: 0.055 to 0.214; p = 0.001). An increased severity of NAFLD was associated with worse diastolic indices (decreased E/A ratio, p = 0.007), but not with systolic indices.

Conclusions

NAFLD is associated with impaired systolic and diastolic function with changes in cardiac structure. Concomitant metabolic risk factors and liver disease severity are independently associated with worsening systolic and diastolic function.

Graphical abstract

Nur mit Berechtigung zugänglich

Muthiah MD, Sanyal AJ. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol Clin North Am 2020;49(1):1–23CrossRefPubMed

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84CrossRefPubMed

Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know. Diabetes Obes Metab 2021;24(2):3–14PubMed

Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18(4):223–238CrossRefPubMed

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328–357CrossRefPubMed

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–1402

Azzam H, Malnick S. Non-alcoholic fatty liver disease - the heart of the matter. World J Hepatol 2015;7(10):1369–1376CrossRefPubMedPubMedCentral

Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355(3):260–269CrossRefPubMed

VanWagner LB, Wilcox JE, Ning H, et al. Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: The CARDIA Study. J Am Heart Assoc 2020;9(4): e014279CrossRefPubMedPubMedCentral

10.

Borges-Canha M, Neves JS, Libânio D, et al. Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis. Endocrine 2019;66(3):467–476CrossRefPubMed

11.

Baragetti A, Pisano G, Bertelli C, et al. Subclinical atherosclerosis is associated with epicardial fat thickness and hepatic steatosis in the general population. Nutr Metab Cardiovasc Dis 2016;26(2):141–153CrossRefPubMed

12.

Wijarnpreecha K, Lou S, Panjawatanan P, et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig Liver Dis 2018;50(11):1166–1175CrossRefPubMed

13.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:71CrossRef

14.

Toh JZK, Pan X-H, Tay PWL, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2021. https://doi.org/10.1016/j.cgh.2021.09.021CrossRefPubMed

15.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129–2200CrossRefPubMed

16.

Hsu PF, Wang YW, Lin CC, et al. The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population. Liver Int 2021;41(1):81–90CrossRefPubMed

17.

Bae YS, Ko YS, Yun JM, Eo AY, Kim H. Association and prediction of subclinical atherosclerosis by nonalcoholic fatty liver disease in asymptomatic patients. Can J Gastroenterol Hepatol 2020;2020:8820445CrossRefPubMedPubMedCentral

18.

Kim MK, Ahn CW, Nam JS, Kang S, Park JS, Kim KR. Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. Menopause 2015;22(12):1323–1327CrossRefPubMedPubMedCentral

19.

IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 2014;14(1):25CrossRefPubMedPubMedCentral

20.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557CrossRefPubMedPubMedCentral

21.

Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In. 9.5.2 Identifying and measuring heterogeneity: The Cochrane Collaboration; 2011

22.

Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc 2015;13(3):196–207CrossRefPubMed

23.

Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 2014;3(3):123–128CrossRefPubMedPubMedCentral

24.

Aksu E, Sokmen A, Ispiroglu M, Gisi K, Celik E, Aykan AC. Early cardiac electrical and structural changes in patients with non-obese non-alcoholic fatty liver disease. Kardiologiia 2021;61(5):51–58CrossRefPubMed

25.

Baktir AO, Şarli B, Emre Altekin R, et al. Non alcoholic steatohepatitis is associated with subclinical impairment in left ventricular function measured by speckle tracking echocardiography. Anatol J Cardiol 2015;15(2):137–142CrossRefPubMed

26.

Fotbolcu H, Yakar T, Duman D, et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 2010;17(5):457–463PubMed

27.

Karabay CY, Kocabay G, Kalayci A, et al. Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur J Gastroenterol Hepatol 2014;26(3):325–331CrossRefPubMed

28.

Oguz D, Unal HU, Eroglu H, Gulmez O, Cevik H, Altun A. Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Anatol J Cardiol 2016;16(12):974–979PubMedPubMedCentral

29.

Sunbul M, Agirbasli M, Durmus E, et al. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis 2014;237(2):490–493CrossRefPubMed

30.

Sunbul M, Kivrak T, Durmus E, et al. Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc Ther 2015;33(5):294–299CrossRefPubMed

31.

Topuz M, Dogan A, Celik A, Can C, Ozdogru I, Kemal EN. Investigation of the relationship between non-alcoholic fatty liver disease and coronary artery disease. Clin Ter 2014;165(1):e46–51PubMed

32.

Yilmaz Y, Kurt R, Gurdal A, et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 2011;217(1):125–129CrossRefPubMed

33.

Cho KI, Jo EA, Cho SH, Kim BH. The influence of epicardial fat and nonalcoholic fatty liver disease on heart rate recovery in metabolic syndrome. Metab Syndr Relat Disord 2017;15(5):226–232CrossRefPubMed

34.

Chung GE, Lee JH, Lee H, et al. Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis 2018;272:137–144CrossRefPubMed

35.

Jung JY, Park SK, Ryoo JH, et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol Res 2017;47(6):522–532CrossRefPubMed

36.

Kim NH, Park J, Kim SH, et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014;100(12):938–943CrossRefPubMed

37.

Lee H, Kim G, Choi YJ, et al. Association between non-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus. Diabetes Metab J 2020;44(2):267–276CrossRefPubMed

38.

Lee M, Kim KJ, Chung TH, et al. Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. Diabetes Obes Metab 2021;23(4):1041–1051CrossRefPubMed

39.

Lee YH, Kim KJ, Yoo ME, et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol 2018;68(4):764–772CrossRefPubMed

40.

Brouha SS, Nguyen P, Bettencourt R, Sirlin CB, Loomba R. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: a prospective study. Eur Radiol 2018;28(4):1345–1355CrossRefPubMed

41.

Donnellan E, Cotter TG, Wazni OM, et al. Impact of nonalcoholic fatty liver disease on arrhythmia recurrence following atrial fibrillation ablation. JACC Clin Electrophysiol 2020;6(10):1278–1287CrossRefPubMed

42.

Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring, Md) 2014;22(2):332–336CrossRef

43.

Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep 2020;10(1):12440CrossRefPubMedPubMedCentral

44.

Chang W, Wang Y, Sun L, Yu D, Li Y, Li G. Evaluation of left atrial function in type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional speckle tracking echocardiography. Echocardiography (Mount Kisco, NY) 2019;36(7):1290–1297CrossRef

45.

Huang J, Huang Q, Chen XZ, Zhou F, He JQ, Wang XL. A study of the relationship between cardiac diastolic function and liver function in patients with nonalcoholic fatty liver disease. World Chin J Digestol 2009;17(21):2198–2202CrossRef

46.

Wang Q, Ma W, Xia J. Nonalcoholic fatty liver is associated with further left ventricular abnormalities in patients with type 2 diabetes mellitus: a 3-dimensional speckle-tracking study. J Ultrasound Med 2018;37(8):1899–1911CrossRefPubMed

47.

Zhang Z, Wang P, Guo F, et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. J Int Med Res 2018;46(9):3959–3969CrossRefPubMedPubMedCentral

48.

Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012;35(2):389–395CrossRefPubMedPubMedCentral

49.

Fallo F, Dalla Pozza A, Sonino N, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009;19(9):646–653CrossRefPubMed

50.

Mantovani A, Pernigo M, Bergamini C, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One 2015;10(8): e0135329CrossRefPubMedPubMedCentral

51.

Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol 2016;221:275–279CrossRefPubMed

52.

Elsawaby AS, Al-Fiky RA, Mohamed AE, et al. Electrocardiographic and echocardiographic changes in nonalcoholic fatty liver disease. Egypt J Internal Med 2019;31(2):191–198CrossRef

53.

Mahfouz RA, Gouda M, Galal I, Ghareb MS. Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. Echocardiography (Mount Kisco, NY) 2019;36(2):249–256CrossRef

54.

Metwaly A, Khalik AA, Nasr FM, Sabry AI, Gouda MF, Hassan M. Brain natriuretic peptide in liver cirrhosis and fatty liver: correlation with cardiac performance. Electron Physician 2016;8(2):1984–1993CrossRefPubMedPubMedCentral

55.

Khoshbaten M, Parkhideh S, Toufan M. Comparison of left ventricular function between patients with non-alcoholic fatty liver disease and healthy individuals. Biomed Pharmacol J 2015;8(2):749–754CrossRef

56.

Zamirian M, Samiee E, Moaref A, Abtahi F, Tahamtan M. Assessment of subclinical myocardial changes in non-alcoholic fatty liver disease: A case-control study using speckle tracking echocardiography. Iran J Med Sci 2018;43(5):466–472

57.

Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006;40(10):949–955CrossRefPubMed

58.

Psychari SN, Rekleiti N, Papaioannou N, et al. Epicardial fat in nonalcoholic fatty liver disease: properties and relationships with metabolic factors, cardiac structure, and cardiac function. Angiology 2016;67(1):41–48CrossRefPubMed

59.

de Freitas Diniz TB, de Jesus RN, Jimenez LS, Pareja JC, Chaim EA, Cazzo E. Non-alcoholic fatty liver disease is associated with impairment of ejection fraction among individuals with obesity undergoing bariatric surgery: results of a cross-sectional study. Obes Surg 2020;30(2):456–460CrossRefPubMed

60.

Moise CG, Donoiu I, Tartea G-C, Mirea O, Rogoveanu I. Assessment of left ventricular diastolic function in young adults with nonalcoholic fatty liver disease. Curr Health Sci J 2021;47(1):23–27PubMedPubMedCentral

61.

Sewan HS, Aljumaily HS. Frequency of left ventricle dysfunction in non-alcoholic fatty liver disease (Nafld) patients detected by global longitudinal strain and tissue Doppler imaging in Babylon province in Iraq. Medico-Legal Update 2021;21(1):1380–1386

62.

Styczynski G, Kalinowski P, Michalowski L, et al. Cardiac morphology, function, and hemodynamics in patients with morbid obesity and nonalcoholic steatohepatitis. J Am Heart Assoc 2021;10(8):e017371CrossRefPubMedPubMedCentral

63.

Saluja M, Kumar K, Swami YK, Meena SR, Goyal S. Association between non- alcoholic fatty liver disease and left ventricular diastolic dysfunction in patients of type 2 diabetes. J Assoc Physicians India 2019;67(8):20–24PubMed

64.

Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28(1):27–38CrossRefPubMed

65.

Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009;104(4):861–867CrossRefPubMed

66.

Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9(6):524–530CrossRefPubMed

67.

Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29(1):113–119CrossRefPubMed

68.

Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Dig Liver Dis 2016;48(3):333–342CrossRefPubMed

69.

Mikolasevic I, Milic S, Turk Wensveen T, et al. Nonalcoholic fatty liver disease—a multisystem disease? World J Gastroenterol 2016;22(43):9488–9505CrossRefPubMedPubMedCentral

70.

Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 2015;62(4):928–933CrossRefPubMed

71.

Pacifico L, Di Martino M, De Merulis A, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2014;59(2):461–470CrossRefPubMed

72.

Mitter SS, Shah SJ, Thomas JD. A test in context: E/A and E/e’ to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol 2017;69(11):1451–1464CrossRefPubMed

73.

Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54(8):1013–1025CrossRefPubMed

74.

Canada JM, Abbate A, Collen R, et al. Relation of hepatic fibrosis in nonalcoholic fatty liver disease to left ventricular diastolic function and exercise tolerance. Am J Cardiol 2019;123(3):466–473CrossRefPubMed

75.

Sanchez AA, Levy PT, Sekarski TJ, et al. Markers of cardiovascular risk, insulin resistance, and ventricular dysfunction and remodeling in obese adolescents. J Pediatr 2015;166(3):660–665CrossRefPubMed

76.

Belke DD, Betuing S, Tuttle MJ, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002;109(5):629–639CrossRefPubMedPubMedCentral

77.

Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol 2014;63(5):407–416CrossRefPubMed

78.

Liu B, Li Y, Li Y, et al. Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis. Hep Intl 2019;13(6):757–765CrossRef

79.

Dai S, Harrist RB, Rosenthal GL, Labarthe DR. Effects of body size and body fatness on left ventricular mass in children and adolescents: Project HeartBeat! Am J Prev Med 2009;37(1 Suppl):S97–104CrossRefPubMedPubMedCentral

80.

Ratziu V, Sanyal AJ, Loomba R, et al. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019;84:105803CrossRefPubMed

81.

Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018;68(1):361–371CrossRefPubMed

Titel: Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis
verfasst von: Jie Ning Yong
Cheng Han Ng
Chloe Wen-Min Lee
Yu Yi Chan
Ansel Shao Pin Tang
Margaret Teng
Darren Jun Hao Tan
Wen Hui Lim
Jingxuan Quek
Jieling Xiao
Yip Han Chin
Roger Foo
Mark Chan
Weiqin Lin
Mazen Noureddin
Mohammad Shadab Siddiqui
Mark D. Muthiah
Arun Sanyal
Nicholas W. S. Chew
Publikationsdatum: 23.03.2022
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 2/2022
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-022-10319-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL

Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease

Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma

Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis